公开(公告)号：US09573972B2

公开(公告)日：2017-02-21

申请号：US13126704

申请日：2009-10-30

Applicant: Christopher Ariel Shaw ,  Denis George Kay

Inventor： Christopher Ariel Shaw ,  Denis George Kay

IPC: C07J17/00 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07J17/00 ,  A01K2267/035 ,  G01N33/5088 ,  G01N33/6896

Abstract: The invention relates to compositions for use in animal models of neurodegenerative disease and methods therefor. More particularly, the invention relates to the use of neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof, in animal models of neurodegenerative disease. Neurotoxicity-modulating chromenols can also be used in these animal models in combination with the neurotoxic sterol glycosides or neurotoxic glycolipids, or combinations thereof.

Abstract translation: 本发明涉及用于神经变性疾病的动物模型的组合物及其方法。 更具体地说，本发明涉及在神经变性疾病的动物模型中使用神经毒性甾醇糖苷或神经毒性糖脂或其组合。 神经毒性调节色烯醇也可以与神经毒性甾醇糖苷或神经毒性糖脂或其组合结合使用在这些动物模型中。

公开(公告)号：US09557323B2

公开(公告)日：2017-01-31

申请号：US13581483

申请日：2011-09-26

Applicant: Sofia A. Casares ,  Teodor D. Brumeanu ,  Thomas L. Richie

Inventor： Sofia A. Casares ,  Teodor D. Brumeanu ,  Thomas L. Richie

IPC: A01K67/027 ,  G01N33/50 ,  A61D19/04

CPC classification number: G01N33/5088 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A61D19/04

Abstract: Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development. More specifically, a mouse model capable of expressing human leukocyte antigen DR4, and human costimulatory molecules (CD80) upon infusion of human HLA-matched hematopoietic stem cells, which can develop into a functional human immune system is provided.

Abstract translation: 提供了用于测试人类疫苗的免疫原性和保护功效的转基因动物模型以及产生这种多转基因动物的方法。 还公开了筛选用于人类疫苗开发的组合物的方法。 更具体地，提供了能够发展成功能性人免疫系统的能够表达人白细胞抗原DR4的小鼠模型，以及输入人类HLA匹配造血干细胞后的人共刺激分子（CD80）。

公开(公告)号：US20170014552A1

公开(公告)日：2017-01-19

申请号：US15274422

申请日：2016-09-23

Applicant: Tepha, Inc.

Inventor： David P. Martin ,  Simon F. Williams

IPC: A61L31/06 ,  C12P7/62 ,  A61L27/18 ,  C08G63/90 ,  A61L31/10 ,  A61L17/10 ,  C08G63/06

CPC classification number: A61L31/06 ,  A61L17/105 ,  A61L27/18 ,  A61L27/34 ,  A61L31/10 ,  C08G63/06 ,  C08G63/90 ,  C12P7/625 ,  G01N33/5088 ,  Y10T436/201666 ,  C08L67/04

Abstract: Compositions of P4HB with high purity have been developed. The compositions are prepared by washing P4HB biomass prior to solvent extraction, and precipitating P4HB from solution. The same solvent is preferably used to wash the P4HB biomass, and as a non-solvent to precipitate the polymer from a P4HB solvent solution. The highly pure P4HB compositions are suitable for preparing implants. The implants may be used for the repair of soft and hard tissues.

Abstract translation: 已经开发了高纯度的P4HB组合物。 通过在溶剂萃取之前洗涤P4HB生物质并从溶液中沉淀P4HB来制备组合物。 优选使用相同的溶剂来洗涤P4HB生物质，并且作为非溶剂以从P4HB溶剂溶液中沉淀聚合物。 高纯度的P4HB组合物适用于制备植入物。 植入物可用于修复软组织和硬组织。

公开(公告)号：US20160345548A1

公开(公告)日：2016-12-01

申请号：US15237165

申请日：2016-08-15

Applicant: The Jackson Laboratory ,  University of Massachusetts

Inventor： Leonard D. Shultz ,  Dale L. Greiner ,  Michael A. Brehm

IPC: A01K67/027 ,  G01N33/50

CPC classification number: A01K67/0276 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2207/20 ,  A01K2217/056 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0387 ,  G01N33/5023 ,  G01N33/5088 ,  G01N2333/70596

Abstract: Described herein are immunodeficient non-human animals lacking expression of toll-like receptor 4 (TLR4) by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient non-human animal lacking expression of toll-like receptor 4 (TLR4), thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells. Further described are immunodeficient mice lacking expression of toll-like receptor 4 by endogenous autogeneic innate immune cells, as well as methods and compositions for engraftment of xenogeneic hematopoietic stem cells in the immunodeficient mouse lacking expression of toll-like receptor 4, thereby creating an innate immune system in the animal derived from the xenogeneic hematopoietic stem cells.

公开(公告)号：US09506912B2

公开(公告)日：2016-11-29

申请号：US14518070

申请日：2014-10-20

Applicant: Massachusetts Institute of Technology

Inventor： Mehmet F. Yanik ,  Steven C. Wasserman ,  Tsung-Yao Chang ,  Cody L. Gilleland ,  Carlos Pardo

IPC: G01N21/15 ,  G01N35/00 ,  C40B30/06 ,  C40B60/10 ,  G01N33/50 ,  G01N21/05 ,  G01N15/14 ,  G01N1/14 ,  G01N1/28

CPC classification number: G01N33/5088 ,  C40B30/06 ,  C40B60/10 ,  G01N1/14 ,  G01N1/28 ,  G01N15/1475 ,  G01N21/05 ,  G01N35/00

Abstract: High throughput system for in vivo screens on vertebrate larvae. The system includes a source of vertebrate larvae in a liquid medium and loading tube means for aspirating a larva. A detector assembly is provided to differentiate passage of a larva from bubbles and/or debris. An imaging means is provided for both confocal imaging and wide-field fluorescence imaging of the larva. A laser is provided for optical manipulation of the larva.

Abstract translation: 用于脊椎动物幼虫体内筛选的高通量系统。 该系统包括液体介质中的脊椎动物幼体来源和用于吸入幼虫的装载管装置。 提供检测器组件以将幼虫的通道与气泡和/或碎屑区分开来。 为共同成像和幼虫的大面积荧光成像提供成像装置。 提供激光器用于幼虫的光学操作。

公开(公告)号：US20160295854A1

公开(公告)日：2016-10-13

申请号：US15030982

申请日：2014-07-30

Applicant: UNIAO BRASILEIRA DE EDUCACAO E ASSISTENCIA , MANTENEDORA DA PUCRS

Inventor： Cristina Beatriz Cazabuena Bonorino ,  Thiago de Jesus Borges

IPC: A01N1/02 ,  G01N33/50

CPC classification number: A01N1/0226 ,  A01N1/021 ,  A61K38/063 ,  A61K38/1774 ,  G01N33/505 ,  G01N33/5088

Abstract: A composition for modulating MARCH-I, MHC II and/or CD86 in the cells of an organ taken from a donor for subsequent transplantation in a recipient. The composition has one or more organ preservation solutions in combination with an Hsp. The composition may comprise Hsp70 and/or one or more synthetic Hsp70-derived peptides. The composition provides preservation while at the same time reducing rejection of an organ, preserving the useful life of the organ, initiating a process in the organ which inhibits acute rejection, lengthening the useful life of the organ in vivo, having local immunomodulating effects in the recipient, having an indirect impact on the quality of life of the transplant recipient by necessitating fewer immunosuppressive medications, inducing the activity of regulatory T cells, reducing the expression of MHC molecules in the graft, reducing alloreactive expression in the recipient's lymph nodes, and lengthening the survival of the graft in the recipient.

Abstract translation: 用于在接受者随机移植的供体器官细胞中调节MARCH-1，MHC II和/或CD86的组合物。 该组合物具有与Hsp组合的一种或多种器官保存溶液。 组合物可以包含Hsp70和/或一种或多种合成的Hsp70衍生的肽。 组合物提供保存，同时减少器官的排斥，保持器官的使用寿命，在器官中起始抑制急性排斥反应的过程，延长器官在体内的使用寿命，具有局部免疫调节作用 受体，通过需要较少的免疫抑制药物，诱导调节性T细胞的活性，减少移植物中MHC分子的表达，减少接受者的淋巴结中的同种异体反应物的表达和延长，对移植受体的生活质量产生间接影响 移植物在接受者的生存。

公开(公告)号：US09463224B2

公开(公告)日：2016-10-11

申请号：US14551291

申请日：2014-11-24

Applicant: Charles N. S. Soparkar

Inventor： Charles N. S. Soparkar

IPC: A61K38/48 ,  A61K9/48 ,  A61K47/00 ,  A61K38/46 ,  A23L1/304 ,  A61K33/30 ,  A61K39/08 ,  G01N33/50

CPC classification number: A61K38/465 ,  A23L33/16 ,  A23L33/165 ,  A61K33/30 ,  A61K38/4893 ,  A61K39/08 ,  C12Y301/03008 ,  C12Y301/03026 ,  C12Y304/24069 ,  G01N33/5088 ,  G01N2800/52 ,  G01N2800/709 ,  A61K2300/00

Abstract: Methods and compositions are provided for increasing responsiveness to therapeutic metalloproteases including increasing and/or maximizing responsiveness and preventing botulinum and tetanus toxin resistance due to a functional deficiency of zinc. Also provided are methods for zinc replacement or supplement in lacking individuals comprising the administration of a zinc supplement for a loading period and/or administration of a phytase supplement together with the zinc supplement. Also provided are methods for standardization of botulinum toxin potency assays that provide for greater certainty and margins of safety in the use of products from different manufacturers.

公开(公告)号：US09462794B2

公开(公告)日：2016-10-11

申请号：US14882531

申请日：2015-10-14

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Andrew J. Murphy ,  O. Gavin Thurston ,  Bindu Varghese ,  Cagan Gurer

IPC: C12N15/90 ,  A01K67/027 ,  C12N5/10 ,  A61K49/00 ,  C12N15/85 ,  C12N15/89 ,  G01N33/50 ,  C12N9/16 ,  C07K14/705

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2227/10 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0331 ,  A01K2267/0381 ,  A01K2267/0387 ,  A61K49/0008 ,  C07K14/70503 ,  C07K14/70596 ,  C07K16/2809 ,  C07K16/2887 ,  C07K2317/31 ,  C07K2319/00 ,  C12N9/16 ,  C12N15/8509 ,  C12N15/89 ,  C12N15/902 ,  C12N15/907 ,  C12N2015/8518 ,  C12N2015/8527 ,  C12N2015/8572 ,  C12N2800/30 ,  C12Y301/03048 ,  G01N33/5011 ,  G01N33/5088 ,  G01N2500/04 ,  G01N2500/10

Abstract: Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

公开(公告)号：US20160280760A1

公开(公告)日：2016-09-29

申请号：US15083106

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K45/06 ,  C07K16/28 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20160280752A1

公开(公告)日：2016-09-29

申请号：US15083139

申请日：2016-03-28

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/47 ,  C07K16/28 ,  C07K14/725 ,  A61K45/06 ,  G01N33/569 ,  A61K39/00 ,  C07K16/30

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.